Navigation Links
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
Date:10/31/2013

ENMD-2076 in this difficult to treat patient population.  We look forward to working closely with EntreMed and colleagues from other sites in this Phase 2 trial."

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer commented, "We are very pleased to have Dr. Oza lead this trial.  Dr. Oza was a principal investigator in our Phase 2 study in platinum resistant ovarian cancer and has been instrumental in advancing our development program targeting this indication.  The cumulative evidence has indicated the potential effectiveness of a combined anti-angiogenic and anti-Aurora A targeted approach in OCCC, and we believe ENMD-2076 presents strong clinical and scientific rationale for the treatment of this subset of patient population.  This trial will provide us with more insight into the drug's clinical activities and its correlation with biomarkers."

Dr. Ren further commented, "Together with our trials in triple negative breast cancer and soft tissue sarcoma, this is the third clinical trial we have initiated for ENMD-2076 under our US/China development model.  We intend to expand the trial into China once we have it underway in Canada and the US.  Our goal is to reach a clinical inflection point using a cost-effective approach that combines speed, quality and lower costs, in order to maximize the value proposition of ENMD-2076. We are confident that we will reach this goal."

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Second Quarter 2013 Financial Results
2. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
3. EntreMed Reports First Quarter 2013 Financial Results
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
10. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
11. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014  UBM Medica US announces that Endocrinology ... other clinicians who treat patients with type 2 ... use of insulin .  Nearly all ... therapy – daily injections of one or more ... the function of pancreatic beta cells. Insulin is a ...
(Date:10/17/2014)... 17, 2014  Ameritox SM , the nation,s leader ... Thomas Smith , M.D., as Chief Medical Officer. ... offering scientific resources for healthcare providers, patients and managed ... positions at a variety of healthcare companies that have ... pain and behavioral health sides of Ameritox,s business. He ...
(Date:10/17/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro® is now being used ... 140,000 square foot, 44-bed hospital with many outpatient services. ... a large number of Native Americans from several tribes ... beyond. A portion of its funding comes from the ...
Breaking Medicine Technology:Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, ... estimates member hospital ROI on membership dues at 12.5. In ... provides $12.50 in value to member hospitals. The calculation used ... Dues)/Member Dues. , “This is the first time we’ve ... think the methodology is really sound,” said Bill Ryan ...
(Date:10/20/2014)... 20, 2014 Punzoné , the first ... U.S., has a lot to celebrate this month. October marks ... the achievements and contributions of Americans of Italian heritage and ... and today it shares its favorite Italian cocktails and encourages ... Italy - even if it is only in a glass. ...
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... regulating cholesterol in the bloodstream also appears to affect progesterone ... substantial number of cases of their infertility, a new study ... has also developed a simple blood test for this variation ... but emphasized there is no approved therapy yet to address ...
... 2011)Today,s anticancer drugs often work wonders against malignancies, but ... drugs, and treatment fails. Medical researchers would like to ... must understand why and how it happens. New findings ... Abcc10 (also known as Mrp7), as being intimately involved ...
... Critical new research has found that lesbian, gay, bisexual, ... school victimization in middle and high school report impaired ... suicide attempts that require medical care, sexually transmitted diseases ... known study to examine the relationship between school victimization ...
... with advanced prostate cancer suggest they can be good ... study found a 20-year survival rate for 80 percent ... beyond the prostate, known as cT3 prostate cancer, and ... prostate gland. Previously, patients found to have cT3 prostate ...
... DENVER Continuous positive airway pressure (CPAP) effectively decreases ... suffer from obstructive sleep apnea (OSA), according to a ... the first large-scale study to assess the impact of ... mortality in the elderly. The findings will be ...
... Patients with small kidney tumors are more likely ... volume and type of practice than on tumor characteristics, ... practice in academic medical centers with high volumes of ... more likely to follow American Urological Association (AUA) guidelines ...
Cached Medicine News:Health News:Gene variation linked to infertility in women, study finds 2Health News:Gene variation linked to infertility in women, study finds 3Health News:Abcc10 may be effective in extending the effectiveness of anticancer drugs 2Health News:Abcc10 may be effective in extending the effectiveness of anticancer drugs 3Health News:School bullying, violence against LGBT youth linked to risk of suicide, HIV infection 2Health News:School bullying, violence against LGBT youth linked to risk of suicide, HIV infection 3Health News:CPAP decreases cardiovascular mortality in elderly patients 2Health News:CPAP decreases cardiovascular mortality in elderly patients 3
Selute Picotip Atrial-J steroid eluting passive fixation lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: